Agilent Technologies Named 2017 Company of the Year by IBO

LOS ANGELES, Jan. 16, 2018 -- IBO today named Agilent Technologies (Santa Clara, CA) the 2017 Company of the Year. IBO is the leading newsletter tracking trends and developments in the analytical and life science instrumentation, and laboratory products markets.

"Agilent has grown sales since fiscal 2015 while keeping costs constant,” said Tanya Samazan, Managing Editor of IBO. “The company’s fiscal 2017 revenue growth was its fastest since fiscal 2010.”

IBO monitors hundreds of life science and analytical instrument companies on a daily basis, continually tracking financial developments and new market entries. "Agilent’s new investments have also paid off,” explained Samazan. “Changes include an expansion of Agilent’s diagnostics business, entry into new markets such as cell analysis and Raman spectroscopy, and additions to successful franchises in NGS sample preparation and LC/MS, among other key product launches."

IBO's annual Company of the Year award is featured in the publication's 2018 Industry Forecast Issue, now available for purchase. The 36-page Forecast Issue highlights trends and projects expected growth in 10 major segments of the life science, analytical instrument and consumables markets, as well as an analysis of regional and end-market developments.

ABOUT IBO and SDi

Instrument Business Outlook (IBO) provides expert insights, commentary and analysis of the news, trends and developments impacting the life science, analytical instrument and consumables markets. A twice-monthly subscription-based newsletter, IBO is a publication of SDi, a division of BioInformatics LLC. SDi offers custom market research and consulting, and strategic advisory services in the areas of M&A support, opportunity analysis, end-user surveys, and situation analysis, as well as licensing, joint venture, and distribution for top, mid-tier and startup companies. IBO and SDi’s data analyses and solutions are used by corporate executives, business development personnel, equity and financial analysts, regulatory agencies, technology developers and the scientific/analytical instrument community in the United States and internationally.

www.gene2drug.com

For more information contact:
Tanya Samazan
Managing Editor
Instrument Business Outlook
A publication of SDi
6242 Westchester Parkway, Suite 100
Los Angeles, CA 90045-4820
United States
Phone: 310.641.4982 x64
[email protected] 
www.gene2drug.com